Related Experiment Videos
Combined modality therapy for small cell lung cancer.
1Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
Oncology
|January 1, 1992
Summary
Chemotherapy, including cisplatin/etoposide regimens, improves survival for small cell carcinoma. Combined modality therapy is essential for limited disease, but prophylactic cranial irradiation
Area of Science:
- Oncology
- Medical Research
Background:
- Small cell carcinoma (SCC) is a solid cancer where chemotherapy offers survival benefits.
- Standard chemotherapy regimens include cisplatin/etoposide (PVP) or alternating PVP with cyclophosphamide/doxorubicin/vincristine (CAV).
Purpose of the Study:
- To review the current status of combined modality therapy for small cell carcinoma.
- To discuss essential future clinical trials for SCC treatment.
Main Methods:
- Review of current literature on small cell carcinoma treatment modalities.
- Analysis of the role of chemotherapy, radiotherapy, and surgery in SCC management.
Main Results:
- Chemotherapy, particularly PVP regimens, is effective in prolonging survival for SCC patients.
- Combined modality therapy, especially for limited-stage disease, is crucial for improving treatment outcomes.
- The efficacy and risks of prophylactic cranial irradiation remain unclear due to distant relapses and radiation complications.
Conclusions:
- Combined modality therapy is essential for optimizing small cell carcinoma treatment outcomes.
- Further research is needed to clarify the role and risks of prophylactic cranial irradiation in SCC management.
- Future trials should focus on refining combined treatment strategies and evaluating prophylactic cranial irradiation's impact.